Predict your next investment

Acucela company logo
HEALTHCARE | Drug Discovery
acucela.com

See what CB Insights has to offer

Competitors

13

Business Relationships

7

Service Providers

3

Acucela Competitors & Alternatives

13 Competitors

Acucela has 13 competitors. Acucela's competitors are Lycera, IRX Therapeutics, Romark Global Pharma, DiscoveryBioMed, Xenon Pharmaceuticals and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

4/14/2020

Loan

$87.57M

Michigan

11/7/2018

Acquired

$153.21M

New York

10/10/2015

Debt - II

$189.29M

Florida

4/9/2015

Grant - III

$1.91M

Alabama

11/6/2014

IPO

$98.7M

Canada

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

Latest Funding

4/14/2020

11/7/2018

10/10/2015

4/9/2015

11/6/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Investment Stage

Loan

Acquired

Debt - II

Grant - III

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Total Funding

$87.57M

$153.21M

$189.29M

$1.91M

$98.7M

$99M

$99M

$99M

$99M

Mosaic

Location

Michigan

New York

Florida

Alabama

Canada

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Acucela Service Providers

5 Service Providers

Acucela has 5 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Accounting Firm

Auditor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Subscribe to see more

Subscribe to see more

Provider Type

Accounting Firm

Subscribe to see more

Subscribe to see more

Service Type

Auditor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Acucela Partners & Customers

7 Partners and customers

Acucela has 7 strategic partners and customers. Acucela recently partnered with Sirion Biotech on January 1, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

1/9/2018

Partner

Sirion Biotech

Germany

SIRION Biotech und Acucela beschließen gemeinsame Entwicklung von Gentransfertools in der okularen Gentherapie

SIRION Biotech , ein weltweit führender Experte für Technologieinnovationen und Gentransfer , der maßgeschneiderte Services für kommerzielle Partner weltweit bereitstellt , gab heute den Abschluss eines Zwei-Jahres-Entwicklungsvertrages zur Optimierung Adeno-assoziierter Viren für die klinische Anwendung in der okularen Gentherapie mit Acucela Inc. bekannt .

1

4/5/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/9/2013

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

11/30/2011

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

3/31/2010

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

1/9/2018

4/5/2016

5/9/2013

11/30/2011

3/31/2010

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Sirion Biotech

Country

Germany

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

SIRION Biotech und Acucela beschließen gemeinsame Entwicklung von Gentransfertools in der okularen Gentherapie

SIRION Biotech , ein weltweit führender Experte für Technologieinnovationen und Gentransfer , der maßgeschneiderte Services für kommerzielle Partner weltweit bereitstellt , gab heute den Abschluss eines Zwei-Jahres-Entwicklungsvertrages zur Optimierung Adeno-assoziierter Viren für die klinische Anwendung in der okularen Gentherapie mit Acucela Inc. bekannt .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.